European Commission approves first immunotherapy for high-risk neuroblastoma patients

Written by Jade Parker

The European Commission has approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this group of patients. Affecting around 1200 children every year in Europe, neuroblastoma is the second most common solid tumor in childhood and predominately affects children younger than 5 years of age. The novel immunotherapy from EUSA Pharma (London, UK) approved by the European Commission, dinutuximab beta, is a monoclonal chimeric antibody developed to specifically target the GD2 antigen on neuroblastoma cells. The immunotherapy has been extensively investigated in clinical trials, with over 1000 patients having...

To view this content, please register now for access

It's completely free